7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,731.37

-73.03

-0.10%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqGS - Nasdaq Real Time Price USD

Humacyte, Inc. (HUMA)

0.4482 +0.0527 (+13.32%)

At close: November 6 at 4:00:01 PM EST

0.4508 +0.0026 (+0.58%)

After hours: November 6 at 7:31:01 PM EST

Trade HUMA on Coinbase

Loading Chart for HUMA

Chart Range Bar

Interval:

In partnership with ChartIQ

Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note

Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates

Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026

Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

Mobilize your Website

View Site in Mobile | Classic

Share by: